|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for ITPR3(NM_002224.3) Search again
Product ID:
HQP101223
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
CMT1J, IP3R, IP3R3
Gene Description:
inositol 1,4,5-trisphosphate receptor type 3
Target Gene Accession:
NM_002224.3(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Gene References into function
- IP3R3 may be a prerequisite for secretion of an enzyme, such as protease, in gastric cancer cells; results indicate that IP3R3 may be specifically involved in gastric cancer peritoneal dissemination
- differential expression of the IP(3)R subtype is critical for various forms of Ca(2+) signaling, and, particularly, IP(3)R1 and IP(3)R3 have opposite roles in generating Ca(2+) oscillations
- The estimated population-attributable risk of 21.6% suggests that variation within ITPR3 reflects an important contribution to type 1 diabetes in Sweden.
- Anti-IP(3)R1 antibodies were present in 48.6% of primary Sjogren's syndrome and in 3.0% of normal healthy subjects.
- IP3R3 is present in the paranodal regions of the nodes in the sciatic nerve.
- A functional single nucleotide polymorphism in the NKX2.5-binding site of ITPR3 promoter is associated with susceptibility to systemic lupus erythematosus
- the ankyrin-binding site is located on the cytoplasmic face of the InsP(3) receptor, thus validating the feasibility of in vivo ankyrin-InsP(3) receptor interactions.
- The association between type 1 diabetes and the ITPR3 gene polymorphism due to linkage disequilibrium with HLA class II.
- In this review, by sensing sequential binding of IP3 and calcium ions, the IP3 receptor acts as a coincidence detector that associates parallel fiber inputs with climbing fiber inputs.
- sigma-1R overexpression drives sigma agonist-independent dissociation of ANK 220 from IP3R-3, resulting in activation
- the agonist-induced clustering of IP(3)R is triggered by IP(3) binding, rather than [Ca(2+)](i) elevation.
- May play a role in calcium-dependent nuclear processes.
- IP3-mediated sensitization requires IP3 receptor binding to a TRPV4 C-terminal domain that overlaps with a previously described calmodulin-binding site
- Inability of the T-cell receptors in TCR transgenic mice to trigger calcium mobilization may be due to the insufficient level of inositol 1,4,5-triphosphate receptor (IP3) type 3 to initiate the release of calcium from intracellular stores.
- Results demonstrate the importance of the InsP3 receptor-mutant huntingtin protein association for the pathogenesis of Huntington's disease and as a potential therapeutic target for Huntington's disease.